Semler Scientific Q1 2024 Earnings Report
Key Takeaways
Semler Scientific reported a decrease in revenue by 13% to $15.9 million, but net income increased by 22% to $6.1 million. The company had a strong quarter of cash generation despite the revenue decline. They are seeking a new 510(k) clearance from the FDA to market their heart dysfunction product, which they expect will re-accelerate revenues.
Q1 revenues decreased by 13% to $15.9 million.
Net income increased by 22% to $6.1 million.
Cash, cash equivalents, and restricted cash balance increased to $62.9 million.
Company is seeking FDA clearance for heart dysfunction product to re-accelerate revenues.
Semler Scientific
Semler Scientific
Forward Guidance
Semler Scientific is seeking a new 510(k) clearance from the FDA to market their heart dysfunction product, which they expect will re-accelerate revenues.